Sort by 'likes'
Off-the-shelf Immune Drug for Aggressive Multiple Myeloma: Teclistamab
U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for teclistamab in the treatment of relapsed or refractory multiple myeloma. This follows a PRIME (PRIority MEdicines) designation from the European Medicines Agency (EMA) received earlier this year. …
Wearable EEG’s in Clinical Trials – Now and Beyond
Ensuring technology is viable for clinical studies is the team from Advanced Brain Monitoring with their new product - wearable EEGs. Tune in and learn how this innovative product aids in the study of psychological and neuropsychological conditions that have…
The use of CLR 131 and other targeted radiotherapeutics in pediatric cancers
Many pediatric cancers have very poor overall survival rates once they relapse or if they do not respond to initial standard treatments. Radiotherapy plays an important role in the treatment of these cancers. However, if the cancer has metastasized to…
Waldenstrom’s Macroglobulinemia: Advances in Treatments
Waldenstrom’s macroglobulinemia (WM) is a lymphoma, or cancer of the lymphatic system. The disease begins in a type of white blood cell called a B-lymphocyte, which normally matures into a plasma cell. In WM, there is a malignant change to…
Precision Medicine: Identifying Targeted Cancer Treatments with Genomic Testing
Precision, or personalized, medicine has made a sea-change in cancer treatment. A pipe dream for most patients 10 years ago, it is a reality today. Precision Medicine's keystone is the ability to identify personal gene characteristics and match them to…